DPSG has enjoyed mixed fortunes since its inception as a stand-alone company

DPSG has enjoyed mixed fortunes since its inception as a stand-alone company

Five years ago this week, Dr Pepper Snapple Group began trading as a stand-alone entity on the New York Stock Exchange. The move to becoming a separate publicly-traded company was the result of it being spun off by its owner Cadbury Schweppes. 

On the day DPSG started trading in New York, just-drinks' Chris Brook-Carter noted that it was an inauspicous debut, with investors seemingly "unconvinced of its potential"

So how has it fared since? 

Three months after its demerger, the group announced it was moving into the US energy drinks market, with the launch of Venom.  Later that summer, the company announced it had acquired a miniority stake in low-calorie energy drink Hydrive

DPSG went on the acqusition trail again in August 2008, when it took a minority stake in soda firm Big Red. In December that year, the group got a boost as investor Nelson Peltz upped his stake in the company

However, later that month, the company, which claims Dr Pepper is the "oldest soft drink" in the US having been invented in 1885, reported a full-year net loss of US$312m due to write-down charges relating to a weakening performance in its fourth quarter. 

As 2009 drew to a close, PepsiCo announced it was paying $900m to acquire the manufacturing and distribution rights to some of DPSG's key brands

By 2010, DPSG  was back in the black, reporting net profits of US$555m from 2009 trading. However, this did not stop CEO Larry Young expressing his concern over the threat of legislation around soft drinks. In June, the group pocketed $715m after agreeing a distrbution deal with The Coca-Cola Co in the US and Canada. Later that month it pledged to introduce more low-calorie drinks and smaller pack sizes to reflect the growing demand for healthier products. 

However, the group's fortunes did not improve as it reported that net profits in 2010 slid by around 5%. Things did not improve in the first half of 2011 either. In October, the group launched a push behind its new ten-calorie drink Dr Pepper Ten

For the 2011 full-year, the group increased its profit, off the back of rising sales. But a year later profits slowed slightly, with CEO Young saying the CSD category needed "invigorating". Young also showed a touch of defiance over the increasing threat over health concerns

In its latest Q1, DPSG saw profits up, but volumes slide. 

With it reliance on US markets, its new Ten range so far failing to hit the mark and the pressure on CSD volumes, DPSG may struggle for some time to come.